Last checked at 25 Jan 2023 09:33
LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hikma Pharmaceuticals Share News (HIK)
HIK Share
Price
HIK Share
News2
HIK Share
Chat
HIK Share
Trades
HIK
Live RNS1
HIK Share
Charts
HIK Level 2
Console
HIK Live
Share Price
HIK Broker
Ratings
HIK Directors
Deals
HIK Financial
Diary
HIK
Fundamentals
HIK Short
Positions
HIK
Media
Hikma Pharmaceuticals Information
Share Price Information for Hikma Pharmaceuticals (HIK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,958.00
Bid:
1,750.00
Ask:
2,222.00
Change:
0.00 (0.00%)
Spread:
472.00 (26.971%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
1,958.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.FTSE 250 movers: Shares in Bumi rocket on proposal news
Fri, 02nd Nov 2012 16:23
Mining group Bumi advanced after saying it has appointed Rothschild Goup as its financial adviser with immediate effect to evaluate the proposal received from Long Haul Holdings. Shares in Dixons rose once again, boosted by the news that its main High Street rival, Comet, is likely to go into administration. Also Seymour Pierce has said that John Lewis's strong start to their new Windows 8 range is a positive sign for Dixons. Meanwhile, hotels group Millennium & Copthorne fell despite seeing RevPAR rise 2.6% in the third quarter, with London enjoying an Olympic boost. Hikma Pharmaceuticals also fell after saying it is considering the future of its Generics business as its Eatontown facility in New Jersey continues to be dogged by compliance issues.Gold miner Centamin has once again taken a hit, one day after shares rebounded after returning to the market following a suspension from trade. Earlier this week the firm's shares plummeted after media reports claimed that an Egyptian court had labelled its Sukari mining concession, its primary source of revenue, as void. FTSE 250 - RisersBumi (BUMI) 280.70p +13.05%Dixons Retail (DXNS) 25.60p +9.50%Chemring Group (CHG) 279.00p +7.06%Homeserve (HSV) 236.20p +5.82%Brown (N.) Group (BWNG) 354.10p +4.24%Spectris (SXS) 1,827.00p +3.81%FirstGroup (FGP) 208.00p +3.79%Ruspetro (RPO) 105.00p +3.75%Premier Oil (PMO) 364.70p +3.49%Ferrexpo (FXPO) 227.10p +3.32%FTSE 250 - FallersCentamin (DI) (CEY) 60.80p -9.39%Millennium & Copthorne Hotels (MLC) 479.00p -6.35%Lancashire Holdings (LRE) 847.50p -3.09%Ocado Group (OCDO) 62.25p -3.04%Debenhams (DEB) 120.00p -2.99%Hikma Pharmaceuticals (HIK) 735.00p -2.52%Balfour Beatty (BBY) 312.80p -2.49%Computacenter (CCC) 361.10p -1.69%ICAP (IAP) 330.50p -1.61%BTG (BTG) 336.40p -1.58%NR
More News
18 Jan 2023 15:07
Director dealings: Hikma Pharmaceuticals director snaps up shares
(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.
Read more12 Jan 2023 17:55
Arecor transfers AT307 drug to Hikma for development, regains AT282
(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.
Read more3 Jan 2023 17:31
FTSE 100 ends first trading day of 2023 on upbeat note
FTSE 100 up 1.4%, FTSE 250 adds 1.5%
*Read more3 Jan 2023 09:25
Hikma launches version of Xyrem medicine in US for treating narcolepsy
(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.
Read more3 Jan 2023 09:24
LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:
Read more3 Jan 2023 09:03
LONDON MARKET OPEN: Stocks jump in first session of 2023
(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.
Read more3 Jan 2023 07:58
LONDON BRIEFING: Stocks called higher; China factory sector shrinks
(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.
Read more3 Jan 2023 07:46
Hikma launches generic narcolepsy solution in US
(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.
Read more8 Dec 2022 09:48
LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:
Read more6 Dec 2022 10:48
RBC Capital Markets starts Hikma at 'outperform'
(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.
Read more6 Dec 2022 10:26
LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more15 Nov 2022 12:10
Credit Suisse initiates coverage of Hikma at 'outperform'
(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.
Read more15 Nov 2022 09:58
LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more14 Nov 2022 09:25
LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
Read more